<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00292448</url>
  </required_header>
  <id_info>
    <org_study_id>205.291</org_study_id>
    <nct_id>NCT00292448</nct_id>
  </id_info>
  <brief_title>A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomised, Double-blind, Double-dummy, Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Ba 679 BR Respimat® 5 μg and Tiotropium Inhalation Capsule 18 μg in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this trial is to compare the efficacy and the safety of Ba 679 BR Respimat 5
      ug once daily to tiotropium inhalation capsule 18 ug (Spiriva inhalation capsule) in a
      crossover study of 4-week treatment periods in patients with COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 16-week, multi-centre, randomised, double-blind, double-dummy, crossover study of
      4-week randomised treatment periods to demonstrate the efficacy and safety of 5 ug of Ba 679
      BR inhalation solution from Respimat compared to tiotropium inhalation powder capsule (18 ug)
      via HandiHaler in patients with COPD. The two 4-week randomised treatment periods are
      separated by 4-week washout period.

      Study Hypothesis:

      The primary aim of this trial is to demonstrate non-inferiority of lung function response to
      5 ug (2 actuations of 2.5 ug) of Ba679BR Respimat delivered by the Respimat inhaler once
      daily compared to tiotropium (18 ug) inhaled as powder capsule from the HandiHaler once daily
      at the end of 4-week treatment periods in patients with COPD. The hypothesis test of
      non-inferiority will be performed at alpha = 0.025 (one-sided).

      Comparison(s):

      The primary efficacy endpoint is the trough FEV1 response determined at the end of each
      4-week period of randomised treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date>March 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the trough FEV1 response determined at the end of each 4-week period of randomised treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FVC response after 4 weeks, peak response (FEV1 and FVC) to first dose, peak response (FEV1 and FVC) after 4 weeks, FEV1 AUC0-3h and FVC AUC0-3h response to first dose and after 4 weeks, individual FEV1and FVC measurements at each time point.</measure>
  </secondary_outcome>
  <enrollment>157</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ba 679 BR Respimat</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium (Spiriva) inhalation capsule 18 ug</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        participation in the trial 2. All patients must have a diagnosis of chronic obstructive
        pulmonary disease and must meet the following spirometric criteria:

        ? Patients must have relatively stable, moderate to severe airway obstruction with an FEV1
        =&lt; 70% of predicted normal* and FEV1 =&lt; 70% of FVC (Visits 1 and 2).

        *: Predicted normal values will be calculated according to the formulas for Japanese
        predicted normal values (R05-0607) (see below).

        Males: FEV1 predicted (L) = 0.036 x (height (cm)) ? 0.028 x age (years) ? 1.178 Females:
        FEV1 predicted (L) = 0.022 x (height (cm)) ? 0.022 x age (years) ? 0.005

        ? Patients must maintain stable COPD medications for 1 month prior to Visit 1. 3. Male or
        female patients 40 years of age or older. 4. Patients must be current or ex-smokers with a
        smoking history of more than 10 pack years.

        Pack Years = [Number of cigarettes/ day / 20] x years of smoking 5. Patients must be able
        to perform technically acceptable pulmonary function tests.

        6. Patients must be able to inhale medication in a competent manner from the Respimat
        inhaler and the HandiHaler.

        Patients with/who:

          1. Significant diseases except COPD

          2. Clinically relevant abnormal haematology, blood chemistry, or urinalysis

          3. Recent history of MI

          4. Any cardiac arrhythmia requiring drug therapy or who have been hospitalised for heart
             failure within the past 3 yrs

          5. Cancer within the last 5 yrs

          6. Symptomatic prostatic hypertrophy or bladder neck obstruction

          7. Narrow-angle glaucoma

          8. History of asthma, allergic rhinitis, atopic disease, or who have a total blood
             eosinophil count &gt;= 600 mm3

          9. History of life-threatening pulmonary obstruction, or cystic fibrosis or clinically
             evident bronchiectasis

         10. Active tuberculosis

         11. History of and/or active significant alcohol or drug abuse

         12. Underwent thoracotomy with pulmonary resection

         13. Completed a pulmonary rehabilitation program within the 6 weeks prior to the Scr.
             Visit or who are currently in a pulmonary rehabilitation program

         14. Regularly use daytime oxygen for more than 1 h/day and in the investigator?s opinion
             unable to abstain from the use of oxygen

         15. Took an investigational drug within 1 m or 6 half lives prior to Scr. Visit

         16. Beta-blockers

         17. Anti-allergic drugs or antihistamines for asthma, allergic rhinitis, atopic disease,
             or other allergic disease with a total blood eosinophil count &gt;= 600 mm3

         18. Oral corticosteroids at unstable doses or at doses in excess of the equivalent of 10
             mg of prednisone/day or 20 mg every other day

         19. Hypersensitivity to anticholinergic drugs, or components of the Respimat delivery
             system, to lactose or any other component of the inhalation capsule deliver system

         20. Pregnant or suspect of pregnant or women who are willing to become pregnant during the
             study period or nursing women

         21. Who are currently participating in another study

         22. The randomisation of patients with any respiratory infection or COPD exacerbation in
             the 6 weeks prior to the Scr. Visit or during the scr. period should be postponed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Nippon Boehringer Ingelheim Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Akita, Akita</city>
        <zip>010-1495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bunkyo-ku,Tokyo</city>
        <zip>113-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Habikino, Osaka</city>
        <zip>583-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Inashiki-gun, Ibaraki</city>
        <zip>300-0395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itami, Hyogo</city>
        <zip>664-8540</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamogawa, Chiba</city>
        <zip>296-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kishiwada, Osaka</city>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komaki, Aichi</city>
        <zip>485-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurume, Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsumoto, Nagano</city>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morioka, Iwate</city>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osakasayama, Osaka</city>
        <zip>589-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakai, Osaka</city>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <zip>981-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <zip>984-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seto, Aichi</city>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takatsuki, Osaka</city>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyonaka, Osaka</city>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tsukuba, Ibaraki</city>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wakayama, Wakayama</city>
        <zip>641-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokote, Akita</city>
        <zip>013-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2006</study_first_submitted>
  <study_first_submitted_qc>February 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2006</study_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

